Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 3%, currently up 2.95% at HKD 24.46, with a trading volume of HKD 65.52 million, following the announcement of an upcoming investor meeting to discuss key R&D and business progress [1] Group 1: Company Developments - The company will hold an investor meeting on October 31, 2025, to share the latest advancements in innovative cancer and immune disease treatments [1] - The focus of the meeting will be on the company's new generation antibody-drug conjugate (ATTC) platform and the latest progress of its late-stage pipeline candidates [1] - The first candidate drug from the ATTC platform, HMPL-A251, is a PAM-HER2 ATTC, which combines a highly selective and potent PI3K/PIKK inhibitor as an effective payload with a humanized anti-HER2 IgG1 antibody via a cleavable linker [1] Group 2: Clinical Development - Recent preclinical data for HMPL-A251 was presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targeted Therapy and Cancer Treatment [1] - The company plans to initiate clinical development for HMPL-A251 starting at the end of 2025, with initial studies aimed at evaluating the drug's performance across multiple tumor types with varying HER2 and PAM alteration statuses [1]
和黄医药涨超3% 将于年底开始推动HMPL-A251进入临床开发